107 related articles for article (PubMed ID: 25730350)
1. Service setting impact on costs for bevacizumab-treated oncology patients.
Engel-Nitz NM; Yu EB; Becker LK; Small A
Am J Manag Care; 2014 Nov; 20(11):e515-22. PubMed ID: 25730350
[TBL] [Abstract][Full Text] [Related]
2. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Yang H; Yu AP; Wu EQ; Yim YM; Yu E
J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
[TBL] [Abstract][Full Text] [Related]
3. Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
Parthan A; Santos E; Becker L; Small A; Lalla D; Brammer M; Teitelbaum A
J Manag Care Spec Pharm; 2014 May; 20(5):485-93. PubMed ID: 24761820
[TBL] [Abstract][Full Text] [Related]
4. Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents.
Dacosta Byfield S; Yu E; Morlock R; Evans D; Teitelbaum A
J Med Econ; 2013 Aug; 16(8):1071-81. PubMed ID: 23777222
[TBL] [Abstract][Full Text] [Related]
5. Differences in Health Care Use and Costs Among Patients With Cancer Receiving Intravenous Chemotherapy in Physician Offices Versus in Hospital Outpatient Settings.
Fisher MD; Punekar R; Yim YM; Small A; Singer JR; Schukman J; McAneny BL; Luthra R; Malin J
J Oncol Pract; 2017 Jan; 13(1):e37-e46. PubMed ID: 27845870
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
7. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
8. Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014.
Winn AN; Keating NL; Trogdon JG; Basch EM; Dusetzina SB
JAMA Oncol; 2018 Apr; 4(4):580-581. PubMed ID: 29470578
[TBL] [Abstract][Full Text] [Related]
9. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.
Hedden L; Kennecke H; Villa D; Johnston K; Speers C; Kovacic L; Renouf DJ; Peacock S
Eur J Cancer; 2012 Sep; 48(13):1969-76. PubMed ID: 22325838
[TBL] [Abstract][Full Text] [Related]
10. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
[TBL] [Abstract][Full Text] [Related]
11. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
Dranitsaris G; Ortega A; Lubbe MS; Truter I
J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
[TBL] [Abstract][Full Text] [Related]
12. Same-Day vs Different-Day Elective Upper and Lower Endoscopic Procedures by Setting.
Wang P; Hutfless SM; Shin EJ; Hartman C; Disney S; Fain CC; Bull-Henry KP; Daniels DK; Abdi T; Singh VK; Kalloo AN; Makary MA
JAMA Intern Med; 2019 Jul; 179(7):953-963. PubMed ID: 31081872
[TBL] [Abstract][Full Text] [Related]
13. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
[TBL] [Abstract][Full Text] [Related]
14. [The cost study of first- line treatment of metastatic colorectal carcinoma with bevacizumab- containing regimen in the Czech Republic].
Hradecká I; Ríhová B; Horová R; Demlová R
Klin Onkol; 2014; 27(4):255-60. PubMed ID: 25115714
[TBL] [Abstract][Full Text] [Related]
15. Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer.
Shankaran V; Mummy D; Koepl L; Bansal A; Mirick DK; Yu E; Morlock R; Ogale S; Ramsey SD
Oncologist; 2014 Aug; 19(8):892-9. PubMed ID: 25085899
[TBL] [Abstract][Full Text] [Related]
16. Time for a level playing field: inequalities in regulatory/approval processes—the example of bevacizumab in epithelial ovarian cancer.
Hoskins PJ; Fung-Kee-Fung M; Miller D; Gotlieb W
J Clin Oncol; 2015 May; 33(14):1539-42. PubMed ID: 25847922
[No Abstract] [Full Text] [Related]
17. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
18. Healthcare costs for abortions performed in ambulatory surgery centers vs office-based settings.
Leslie DL; Liu G; Jones BS; Roberts SCM
Am J Obstet Gynecol; 2020 Apr; 222(4):348.e1-348.e9. PubMed ID: 31629727
[TBL] [Abstract][Full Text] [Related]
19. Characterizing medical care by disease phase in metastatic colorectal cancer.
Song X; Zhao Z; Barber B; Gregory C; Schutt D; Gao S
Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP20-5. PubMed ID: 21711074
[TBL] [Abstract][Full Text] [Related]
20. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
